Biopharmaceutical patent protection vs. generic drug competition: Traversing the public policy tightrope

Thomas A. Hemphill

Technology in Society, 2022, vol. 68, issue C

Abstract: The Support Technology & Research for Our Nation's Growth and Economic Resilience (STRONGER) Patents Act, introduced in the 115th Congress, focuses on inter partes review (IPR) and post-grant review (PGR) proceedings that challenge patent validity at the U.S. Patent and Trademark Office, Patent Trial and Appeals Board (PTAB). Quinn, Brachmann, Malone, and Morinville (2018) evaluated patent data for the PTAB covering the first five plus years (through 2017) of the PTAB's operations, and calculate an 82.5% defect rate, i.e., where at least one patent claim is determined invalid and thus the invention not patentable. This finding could signal serious problems either with patent examination quality at the USPTO or with an aggressive PTAB. For recommended future research, further analysis of more recent (2018–21) patent-related validity data should be undertaken, as well as investigating the impact of the recently enacted CREATES Act on the relative strength of biopharmaceutical patent protection.

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0160791X21003249
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:teinso:v:68:y:2022:i:c:s0160791x21003249

DOI: 10.1016/j.techsoc.2021.101849

Access Statistics for this article

Technology in Society is currently edited by Charla Griffy-Brown

More articles in Technology in Society from Elsevier
Bibliographic data for series maintained by Catherine Liu ().